Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04390880 · ClinicalTrials.gov registry record · Phase 2

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

A Phase 2 study, sponsored by VA Greater Los Angeles Healthcare System.

Completed
Registry status
Phase 2
Development phase
239
Enrollment target

NCT04390880: Completed Phase 2 study, sponsored by VA Greater Los Angeles Healthcare System.

NCT04390880 is a Phase 2 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 239 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04390880, a Phase 2 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.

COMPLETED
Registry status
Phase 2
Development phase
239 participants
Enrollment target

Study Summary

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding changes in management will be analyzed. The scan will be used to see how the disease has spread. Both the treatment strategies and probable disease outcomes as relevant to clinical endpoints will be assessed. This study is open to Veterans only.

Primary Outcome

the percentage of patients whose management was changed after PSMA PET/CT

Interventions

  • DRUG 18F-DCFPyL

Trial Details

FieldValue
Enrollment Target 239 participants
Start Date 2020-04-07
Est. Completion 2021-08-31
Phase Phase 2

What the finished NCT04390880 record still lists

NCT04390880 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher).

The record links to 0 conditions, and to 1 intervention - of which 18F-DCFPyL is the first listed.

NCT04390880 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04390880 about?

NCT04390880 is a clinical study titled "18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer". The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by spe...

What is the current status of trial NCT04390880?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2020-04-07. Estimated completion is 2021-08-31.

What interventions are being tested in trial NCT04390880?

The interventions under investigation include: 18F-DCFPyL (DRUG).

Who is sponsoring clinical trial NCT04390880?

This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04390880's enrollment target sits among peer trials

239 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04390880, the US trial registry maintained by the National Library of Medicine. NCT04390880 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.